These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 5597822)
1. [Experience in the therapy of hepatic diseases of unfavorable evolution]. Güemes Díaz F Rev Clin Esp; 1967 Feb; 104(4):327-32. PubMed ID: 5597822 [No Abstract] [Full Text] [Related]
2. Is there a role for high-dose methylprednisolone in the treatment of hepatic regimen-related toxicity? Hennenfent KL; Augustin KM; Dipersio JF; Khoury H Bone Marrow Transplant; 2006 Jan; 37(2):229. PubMed ID: 16284616 [No Abstract] [Full Text] [Related]
3. [Clinical experience with betain citrate (author's transl)]. Babucke G; Sarre B Med Klin; 1973 Aug; 68(34):1109-13. PubMed ID: 4364431 [No Abstract] [Full Text] [Related]
4. [Milk thistle (Silybum marianum) derivatives in the therapy of chronic hepatopathies]. De Martiis M; Fontana M; Assogna G; D'Ottavi R; D'Ottavi O Clin Ter; 1980 Aug; 94(3):283-315. PubMed ID: 7004762 [No Abstract] [Full Text] [Related]
5. [Mefruside in clinical practice: activity and mechanism of action]. Perpignano G; Busilacchi M; Verzetti G Clin Ter; 1969 May; 49(4):337-63. PubMed ID: 5795021 [No Abstract] [Full Text] [Related]
6. [Iontophoresis of Prontosil in liver diseases]. Schmehlik C Dtsch Med Wochenschr; 1970 Jan; 95(5):238. PubMed ID: 5410910 [No Abstract] [Full Text] [Related]
7. [Research on the role of hyperhemolysis in the pathogenesis of hyperbilirubinemia in some hepatic diseases]. Gentilini P; Surrenti C; Sassi R; Salvordi G Riv Crit Clin Med; 1968; 68(3):238-51. PubMed ID: 5737877 [No Abstract] [Full Text] [Related]
8. [Changes in some blood chemical parameters in patients with chronic liver diseases treated with calcium-2,2'-disulfohexanoate]. Turpini R; Scotti A; Brusoni V; Perego M Clin Ter; 1980 Jun; 93(6):689-94. PubMed ID: 7428323 [No Abstract] [Full Text] [Related]
9. Further experience with triamcinolone-demethylchlortetracycline for conservative endodontic treatment. Olsen P J Can Dent Assoc (Tor); 1966 Sep; 32(9):522-6. PubMed ID: 4958143 [No Abstract] [Full Text] [Related]
10. Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease. Smith DL; Shire NJ; Watts NB; Schmitter T; Szabo G; Zucker SD J Clin Densitom; 2006; 9(1):105-13. PubMed ID: 16731439 [TBL] [Abstract][Full Text] [Related]
11. [Clinical and biological efficacy of an hepatic anticytolytic, Bo 714]. Monges H; Salducci J; Deronzier C Therapeutique; 1969 Nov; 45(9):869-74. PubMed ID: 5365411 [No Abstract] [Full Text] [Related]
12. [The effect of chloroquine therapy on the level of porphyrins in the liver in symptomatic hepatic porphyria]. Martásek P; Jirsa M; Kordac V Cesk Gastroenterol Vyz; 1982 Jun; 36(3-4):198-205. PubMed ID: 7105200 [No Abstract] [Full Text] [Related]
13. [Clinical experience in the treatment of chronic liver diseases with Solcohepsyl extralysate]. Arias Vallejo E Folia Clin Int (Barc); 1966 Sep; 16(9):404-15. PubMed ID: 5990974 [No Abstract] [Full Text] [Related]
14. [Clinico-pharmacologic studies on pefloxacin]. Ludwig E; Székely E; Csiba A Orv Hetil; 1994 Mar; 135(13):687-92. PubMed ID: 8170669 [TBL] [Abstract][Full Text] [Related]
15. [Research on the diuretic activity of 7-chloro-2-ethyl-1, 2,3,4-oxo-6-sulfanylquinazoline]. Laurà A Boll Soc Ital Biol Sper; 1965 Feb; 41(3):114-6. PubMed ID: 5875545 [No Abstract] [Full Text] [Related]